IDS and mucopolysaccharidosis type 2: Similarly, a post hoc analysis of data from a 1-year open-label study of 28 patients with MPS II receiving IV idursulfase found associations between safety and efficacy outcomes and genotype, including a more pronounced reduction in liver size among those with missense variants than among those with variants other than missense [39].